Key Stats for Abbott Laboratories Stock
- Price change for Abbott Laboratories stock: 11%
- $ABT Stock Price as of Jul. 16: $99
- 52-Week High: $137
- $ABT Stock Price Target: $117
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Abbott Laboratories (ABT) stock jumped almost 11% on Thursday after the company raised its full-year profit outlook and beat Q2 expectations.
Adjusted earnings came in at $1.31 per share, comfortably above estimates of $1.28 per share. Comparable sales grew 4.8%, an acceleration from the previous two quarters.
Investors had been nervous heading into this report, mostly about Abbott’s acquisition of Exact Sciences. The worry was that the deal would weigh heavily on margins in the near term.
That fear turned out to be overblown. Margins did contract slightly, but by less than expected, and both gross margin and net income came in above forecasts. That gave Abbott Laboratories stock the lift it needed after being oversold relative to its history.
Growth was broad-based across the business. Diagnostics jumped 42.3%, boosted heavily by the Exact Sciences addition and strong Cologuard demand.
Established Pharmaceuticals grew 8.4%, and Medical Devices grew 7.9%. Nutrition was the one soft spot, declining 3.1%, though management said that business is already showing signs of recovery with sequential improvement each month.
CEO Robert Ford said the momentum building in the second half is being driven mainly by four areas: Nutrition, Electrophysiology, Core Lab, and Cancer Diagnostics.
He pointed to strong feedback on new products like the Volt PFA catheter and continued growth in continuous glucose monitoring, which topped $2 billion in sales this quarter.
Abbott also picked up a CE Mark for Libre Duo, the world’s first dual glucose-ketone monitoring sensor, expanding its diabetes care pipeline further.
On guidance, Abbott kept its full-year comparable sales growth target unchanged at 6.5% to 7.5%, but raised the midpoint of its EPS range while narrowing it.
That combination, steady revenue guidance paired with improved profit guidance, tends to signal confidence that margin expansion is durable rather than a one-time bump.
Capital returns remain a key part of the story too. Abbott is a Dividend King with nearly 55 consecutive years of dividend increases, a manageable payout ratio around 70%, and a dividend yield near 2.8% as of mid-July. The company also bought back shares in the quarter, trimming its share count by 0.45%.
See analysts’ growth forecasts and price targets for Abbott Laboratories stock (It’s free) >>>
What the Market Is Telling Us About Abbott Laboratories Stock
The strong reaction in Abbott Laboratories stock suggests the market had priced in more risk from the Exact Sciences deal than was warranted.
With integration now looking smoother than feared, investor attention shifts to Abbott’s broader pipeline, including new cardiovascular devices, expanding diagnostics, and continued momentum in medtech wearables.
Institutional ownership remains high, and analysts appear to be regaining conviction that this quarter marks a turning point rather than a one-off beat.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Abbott Laboratories Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
